ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 9.3% in November

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 12,910,000 shares, a decline of 9.3% from the November 15th total of 14,240,000 shares. Based on an average trading volume of 4,970,000 shares, the short-interest ratio is presently 2.6 days.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ADMA shares. HC Wainwright increased their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday, November 8th. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 3.70% of the company's stock.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds have recently bought and sold shares of ADMA. USA Financial Formulas raised its holdings in shares of ADMA Biologics by 8.6% during the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after acquiring an additional 539 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in shares of ADMA Biologics by 7.0% during the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock valued at $273,000 after acquiring an additional 888 shares during the last quarter. Hollencrest Capital Management acquired a new position in shares of ADMA Biologics during the third quarter valued at approximately $30,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of ADMA Biologics by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock valued at $163,000 after acquiring an additional 1,509 shares during the last quarter. Finally, Larson Financial Group LLC acquired a new position in shares of ADMA Biologics during the third quarter valued at approximately $31,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Price Performance

ADMA stock traded down $0.08 during mid-day trading on Friday, reaching $18.59. 1,979,915 shares of the company's stock were exchanged, compared to its average volume of 3,583,493. The company has a market cap of $4.39 billion, a price-to-earnings ratio of 66.39 and a beta of 0.70. The stock's 50 day moving average is $19.02 and its 200 day moving average is $16.10. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics has a 12-month low of $3.95 and a 12-month high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the prior year, the business posted $0.01 earnings per share. On average, research analysts expect that ADMA Biologics will post 0.52 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.